A Phase 2 interventional study of Glycopyrrolate Inhalation Solution 25mg and Glycopyrrolate Inhalation Solution 75mg in Chronic Obstructive Pulmonary Disease, sponsored by Sunovion Respiratory Development Inc.. Completed. Open to participants aged 40 Years to 75 Years. Per ClinicalTrials.gov, last updated 2018-04-30.
Sponsored by Sunovion Respiratory Development Inc. (part of Sumitomo Pharma Co., Ltd.) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 24 studies in Pulmonary Disease, Chronic Obstructive by Sumitomo Pharma Co., Ltd. — none open to participants now, none under way, none of them phase 3. Pulmonary Disease, Chronic Obstructive · Sumitomo Pharma Co., Ltd..
Among the 24 studies in Pulmonary Disease, Chronic Obstructive by Sumitomo Pharma Co., Ltd., this one is the 24th largest by enrollment, is one of 2 that started in 2009, is one of 7 in phase 2, and was the 22nd registered.
5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 856 are open to participants now.
Browse Pulmonary Disease, Chronic Obstructive studies →None of the 24 studies in Pulmonary Disease, Chronic Obstructive by Sumitomo Pharma Co., Ltd. is open now. The open studies under Pulmonary Disease, Chronic Obstructive, anywhere →
Of the 558 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.
This study: 40 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
24 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 2 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 12 is below the median of 62 across 3,841 interventional studies indexed under Pulmonary Disease, Chronic Obstructive.
Median enrollment 225 across the 24 interventional studies. Of the 24 that completed or were terminated, 15 (63%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Sunovion Respiratory Development Inc., one of the names counted as Sumitomo Pharma Co., Ltd.. Under that name alone:
Sunovion Respiratory Development Inc. is the lead sponsor of 10 studies on the registry; none are open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 24 studies in Pulmonary Disease, Chronic Obstructive by Sumitomo Pharma Co., Ltd., from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The study assessed the safety and ability of several doses of an orally inhaled medicine [ie, Glycopyrrolate Inhalation Solution = GIS] to improve airflow in the lungs when delivered with an electronic eFlow nebulizer system in patients with Chronic Obstructive Pulmonary Disease (COPD). The study was conducted in 12 patients in 2 parts. Part 1 was designed to find the once-a- day GIS dose that produced the highest improvement in lung airflow. Part 2 tested the GIS dose with the highest improvement in lung airflow and a placebo (ie, no drug) delivered by a general purpose nebulizer. The airflow improvements of the same GIS dose were compared between the two nebulizer systems to determine what effect the device had on GIS delivery.
In Part I, 12 subjects were randomly allocated to one of 2 cohorts, running in parallel. The 6 cohort 1 subjects received 25 mg and then 200 mg during their treatment periods 1 and 2, respectively. The 6 cohort 2 subjects received 75mg, 500mg, and 1000 mg during their treatment periods 1, 2, and 3, respectively. During Part II of the study, the same 12 subjects from Part I were randomized to receive either 200 mg jet or placebo in a 1:1 ratio.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
If female and of , must have had a negative pregnancy test and was not lactating at the Screening Visit, and was using one of the following acceptable means of throughout the study:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Glycopyrrolate Inhalation Solution 25 μg via eFlow nebulizer, once daily
Drug: Glycopyrrolate Inhalation Solution 25mg
Glycopyrrolate Inhalation Solution 75 μg via eFlow nebulizer, once daily
Drug: Glycopyrrolate Inhalation Solution 75mg
Glycopyrrolate Inhalation Solution 200 μg via eFlow nebulizer, once daily
Drug: Glycopyrrolate Inhalation Solution 200mg
Glycopyrrolate Inhalation Solution 200 μg via jet nebulizer, once daily
Drug: Glycopyrrolate Inhalation Solution 200mg Jet
Glycopyrrolate Inhalation Solution 500 μg via eFlow nebulizer, once daily
Drug: Glycopyrrolate Inhalation Solution 500mg
Glycopyrrolate Inhalation Solution 1000 μg via eFlow nebulizer, once daily
Drug: Glycopyrrolate Inhalation Solution1000mg
Placebo 0.5 mL via jet nebulizer, once daily
Drug: Placebo
25 μg oral inhalation via eFlow Nebulizer, once daily
Also known as: GIS
75 μg oral inhalation via eFlow Nebulizer, once daily
Also known as: GIS
200 μg oral inhalation via eFlow Nebulizer, once daily
Also known as: GIS
200 μg oral inhalation via inhalation via jet nebulizer, once daily
Also known as: GIS
500 μg oral inhalation via eFlow nebulizer, once daily
Also known as: GIS
1000 μg oral inhalation via eFlow nebulizer, once daily
Also known as: GIS
Placebo 0.5 mL oral inhalation via jet nebulizer, once daily
Number of Subjects Who Died
Time frame: 0-47 days
Number of Subjects With Treatment Emergent SAEs
AEs are defined as existing conditions which worsen or events which occur during the course of the clinical trial after treatment.AEs are defined as existing conditions which worsen or events which occur during the course of the clinical trial after treatment. SAEs are AEs that result in the following outcomes: death, are life-threatening, persistent or significant disability/incapacity, congenital anomaly/birth defect, or important medical events that may have been considered a SAE when, based upon appropriate medical judgment, they may have jeopardized the subject and may have required medical or surgical intervention to prevent one of the outcomes listed in the definition.
Time frame: 0-47 days
Number of Subjects Who Discontinued Due to AE
AEs are defined as existing conditions which worsen or events which occur during the course of the clinical trial after treatment.
Time frame: 0-47 days
Percentage of Subjects With Treatment Emergent AEs
AEs are defined as existing conditions which worsen or events which occur during the course of the clinical trial after treatment.
Time frame: 0-47 days
Number of Subjects With Clinically Significant Abnormal Vital Signs Reported During the Study
Vital signs were measured at screening, during the study (pre-dose, and 30 and 60 minutes and 2, 4, 8, 12, 24 and 30 hours post-dose) and at post study assessment. The clinical significance of each out of normal range vital sign parameter was determined by the investigator during the study.
Time frame: 30 hrs post dose
Number of Subjects With Clinically Significant Abnormal Laboratory Results Reported During the Study
Clinical safety lab parameters were collected at screening and at the post study follow-up assessment. The clinical significance of each out of normal range laboratory parameter was determined by the investigator during the study.
Time frame: day 47 (post studyfollow-up assessment)
Number of Subjects With Clinically Significant ECG Parameters Reported During the Study
ECGs were measured at screening, during the study (pre-dose, and 30 and 60 minutes and 2, 4, 8, 12, 24 and 30 hours post-dose) and at post study follow-up assessment.
Time frame: 30hr post dose
Number of Subjects With Clinically Significant Abnormal Laboratory Results Reported During the Study
Clinical safety lab parameters were collected at screening and at the post study follow-up assessment. The clinical significance of each out of normal range laboratory parameter was determined by the investigator during the study.
Time frame: post study follow-up assessment (Day 47)
Number of Subjects With Treatment Emergent AEs
AEs are defined as existing conditions which worsen or events which occur during the course of the clinical trial after treatment. SAEs are AEs that result in the following outcomes: death, are life-threatening, persistent or significant disability/incapacity, congenital anomaly/birth defect, or important medical events that may have been considered a SAE when, based upon appropriate medical judgment, they may have jeopardized the subject and may have required medical or surgical intervention to prevent one of the outcomes listed in the definition.
Time frame: 0-47 days
Trough FEV1 (Change From Baseline)
Spirometry measurements were conducted in accordance with the current ATS/ERS 2005 guidelines. Trough FEV1 was defined as the spirometry value collected at 24 hours post dose within each Treatment Period.
Time frame: 24hr post dose
Peak FEV1 (Percent Change)
Spirometry measurements were conducted in accordance with the current ATS/ERS 2005 guidelines.
Time frame: 0 to 4hr
Peak FEV1 (Change From Baseline )
Spirometry measurements were conducted in accordance with the current ATS/ERS 2005 guidelines.
Time frame: 0 to 4hr
FEV1 AUC0-24 Area Under the FEV1 Over Time Curve (Change From Baseline)
Spirometry measurements were conducted in accordance with the current ATS/ERS 2005 guidelines.
Time frame: 0 to 24hr post dose
Cmax Maximum Observed Plasma Concentration
Pk parameters are calculated from glycopyrrolate plasma concentration analysed from serial blood samples collected between 0 and 12 hr
Time frame: 0 to 12 hours post dose
Tmax Time to Maximum Observed Plasma Concentration
Pk parameters are calculated from glycopyrrolate plasma concentration analysed from serial blood samples collected between 0 and 12 hr
Time frame: 0 to 12 hours post dose
AUC0-t Area Under the Plasma Concentration-time Curve From Time Zero to the Last Quantifiable Concentration
Pk parameters are calculated from glycopyrrolate plasma concentration analysed from serial blood samples collected between 0 and 12 hr
Time frame: 0 to 12 hourr post dose
AUC0-inf Area Under the Plasma Concentration-time Curve From Time Zero to Infinity
Pk parameters are calculated from glycopyrrolate plasma concentration analysed from serial blood samples collected between 0 and 12 hr
Time frame: 0 to 12 hours post dose
t1/2 Plasma Half-life
Pk parameters are calculated from glycopyrrolate plasma concentration analysed from serial blood samples collected between 0 and 12 hr.
Time frame: 0 to 12 hours post-dose
| Milestone | 25mg Glycopyrrolate, 200mg Gloycopyrrolate | 75mg Glycopyrrolate,500mg Glycopyrrolate,1000mg Glycopyrrolate | 200mg Glycopyrrolate Jet | Placebo |
|---|---|---|---|---|
| Started | 6 | 6 | 0 | 0 |
| Completed | 6 | 6 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 |
| Milestone | 25mg Glycopyrrolate, 200mg Gloycopyrrolate | 75mg Glycopyrrolate,500mg Glycopyrrolate,1000mg Glycopyrrolate | 200mg Glycopyrrolate Jet | Placebo |
|---|---|---|---|---|
| Started | 0 | 0 | 6 | 6 |
| Completed | 0 | 0 | 6 | 6 |
| Not completed | 0 | 0 | 0 | 0 |
| Participants | Glycopyrrolate Inhalation Solution 25mg | Glycopyrrolate Inhalation Solution 75mg | Glycopyrrolate Inhalation Solution 200mg | Glycopyrrolate Inhalation Solution 200mg Jet | Glycopyrrolate Inhalation Solution 500mg | Glycopyrrolate Inhalation Solution1000mg | Placebo 0.5 mL |
|---|---|---|---|---|---|---|---|
| Number of Subjects Who Died | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
AEs are defined as existing conditions which worsen or events which occur during the course of the clinical trial after treatment.AEs are defined as existing conditions which worsen or events which occur during the course of the clinical trial after treatment. SAEs are AEs that result in the following outcomes: death, are life-threatening, persistent or significant disability/incapacity, congenital anomaly/birth defect, or important medical events that may have been considered a SAE when, based upon appropriate medical judgment, they may have jeopardized the subject and may have required medical or surgical intervention to prevent one of the outcomes listed in the definition.
| Participants | Glycopyrrolate Inhalation Solution 25mg | Glycopyrrolate Inhalation Solution 75mg | Glycopyrrolate Inhalation Solution 200mg | Glycopyrrolate Inhalation Solution 200mg Jet | Glycopyrrolate Inhalation Solution 500mg | Glycopyrrolate Inhalation Solution1000mg | Placebo 0.5 mL |
|---|---|---|---|---|---|---|---|
| Number of Subjects With Treatment Emergent SAEs | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
AEs are defined as existing conditions which worsen or events which occur during the course of the clinical trial after treatment.
| Participants | Glycopyrrolate Inhalation Solution 25mg | Glycopyrrolate Inhalation Solution 75mg | Glycopyrrolate Inhalation Solution 200mg | Glycopyrrolate Inhalation Solution 200mg Jet | Glycopyrrolate Inhalation Solution 500mg | Glycopyrrolate Inhalation Solution1000mg | Placebo 0.5 mL |
|---|---|---|---|---|---|---|---|
| Number of Subjects Who Discontinued Due to AE | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
AEs are defined as existing conditions which worsen or events which occur during the course of the clinical trial after treatment.
| percentage of participants | Glycopyrrolate Inhalation Solution 25mg | Glycopyrrolate Inhalation Solution 75mg | Glycopyrrolate Inhalation Solution 200mg | Glycopyrrolate Inhalation Solution 200mg Jet | Glycopyrrolate Inhalation Solution 500mg | Glycopyrrolate Inhalation Solution1000mg | Placebo 0.5 mL |
|---|---|---|---|---|---|---|---|
| Percentage of Subjects With Treatment Emergent AEs | 33.3 | 33.3 | 66.7 | 33.3 | 0.0 | 33.3 | 16.7 |
Vital signs were measured at screening, during the study (pre-dose, and 30 and 60 minutes and 2, 4, 8, 12, 24 and 30 hours post-dose) and at post study assessment. The clinical significance of each out of normal range vital sign parameter was determined by the investigator during the study.
| Participants | Glycopyrrolate Inhalation Solution 25mg | Glycopyrrolate Inhalation Solution 75mg | Glycopyrrolate Inhalation Solution 200mg | Glycopyrrolate Inhalation Solution 200mg Jet | Glycopyrrolate Inhalation Solution 500mg | Glycopyrrolate Inhalation Solution1000mg | Placebo 0.5 mL |
|---|---|---|---|---|---|---|---|
| Number of Subjects With Clinically Significant Abnormal Vital Signs Reported During the Study | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Clinical safety lab parameters were collected at screening and at the post study follow-up assessment. The clinical significance of each out of normal range laboratory parameter was determined by the investigator during the study.
| Participants | Glycopyrrolate Inhalation Solution 25mg | Glycopyrrolate Inhalation Solution 75mg | Glycopyrrolate Inhalation Solution 200mg | Glycopyrrolate Inhalation Solution 200mg Jet | Glycopyrrolate Inhalation Solution 500mg | Glycopyrrolate Inhalation Solution1000mg | Placebo 0.5 mL |
|---|---|---|---|---|---|---|---|
| Number of Subjects With Clinically Significant Abnormal Laboratory Results Reported During the Study | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
ECGs were measured at screening, during the study (pre-dose, and 30 and 60 minutes and 2, 4, 8, 12, 24 and 30 hours post-dose) and at post study follow-up assessment.
| Participants | Glycopyrrolate Inhalation Solution 25mg | Glycopyrrolate Inhalation Solution 75mg | Glycopyrrolate Inhalation Solution 200mg | Glycopyrrolate Inhalation Solution 200mg Jet | Glycopyrrolate Inhalation Solution 500mg | Glycopyrrolate Inhalation Solution1000mg | Placebo 0.5 mL |
|---|---|---|---|---|---|---|---|
| Number of Subjects With Clinically Significant ECG Parameters Reported During the Study | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Clinical safety lab parameters were collected at screening and at the post study follow-up assessment. The clinical significance of each out of normal range laboratory parameter was determined by the investigator during the study.
| Participants | Glycopyrrolate Inhalation Solution 25mg | Glycopyrrolate Inhalation Solution 75mg | Glycopyrrolate Inhalation Solution 200mg | Glycopyrrolate Inhalation Solution 200mg Jet | Glycopyrrolate Inhalation Solution 500mg | Glycopyrrolate Inhalation Solution1000mg | Placebo 0.5 mL |
|---|---|---|---|---|---|---|---|
| Number of Subjects With Clinically Significant Abnormal Laboratory Results Reported During the Study | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
AEs are defined as existing conditions which worsen or events which occur during the course of the clinical trial after treatment. SAEs are AEs that result in the following outcomes: death, are life-threatening, persistent or significant disability/incapacity, congenital anomaly/birth defect, or important medical events that may have been considered a SAE when, based upon appropriate medical judgment, they may have jeopardized the subject and may have required medical or surgical intervention to prevent one of the outcomes listed in the definition.
| Participants | Glycopyrrolate Inhalation Solution 25mg | Glycopyrrolate Inhalation Solution 75mg | Glycopyrrolate Inhalation Solution 200mg | Glycopyrrolate Inhalation Solution 200mg Jet | Glycopyrrolate Inhalation Solution 500mg | Glycopyrrolate Inhalation Solution1000mg | Placebo 0.5 mL |
|---|---|---|---|---|---|---|---|
| Number of Subjects With Treatment Emergent AEs | 2 | 2 | 4 | 2 | 0 | 2 | 1 |
Spirometry measurements were conducted in accordance with the current ATS/ERS 2005 guidelines. Trough FEV1 was defined as the spirometry value collected at 24 hours post dose within each Treatment Period.
| liters | Glycopyrrolate Inhalation Solution 25mg | Glycopyrrolate Inhalation Solution 75mg | Glycopyrrolate Inhalation Solution 200mg | Glycopyrrolate Inhalation Solution 200mg Jet | Glycopyrrolate Inhalation Solution 500mg | Glycopyrrolate Inhalation Solution1000mg | Placebo 0.5 mL |
|---|---|---|---|---|---|---|---|
| Trough FEV1 (Change From Baseline) | 0.038 ± 0.157 | 0.087 ± 0.062 | 0.138 ± 0.079 | -0.013 ± 0.098 | -0.017 ± 0.168 | 0.065 ± 0.072 | -0.030 ± 0.070 |
Spirometry measurements were conducted in accordance with the current ATS/ERS 2005 guidelines.
| percent change | Glycopyrrolate Inhalation Solution 25mg | Glycopyrrolate Inhalation Solution 75mg | Glycopyrrolate Inhalation Solution 200mg | Glycopyrrolate Inhalation Solution 200mg Jet | Glycopyrrolate Inhalation Solution 500mg | Glycopyrrolate Inhalation Solution1000mg | Placebo 0.5 mL |
|---|---|---|---|---|---|---|---|
| Peak FEV1 (Percent Change) | 17.12 ± 9.07 | 15.60 ± 4.20 | 22.98 ± 4.99 | 19.28 ± 13.10 | 11.47 ± 6.86 | 16.87 ± 6.83 | 6.80 ± 2.91 |
Spirometry measurements were conducted in accordance with the current ATS/ERS 2005 guidelines.
| liters | Glycopyrrolate Inhalation Solution 25mg | Glycopyrrolate Inhalation Solution 75mg | Glycopyrrolate Inhalation Solution 200mg | Glycopyrrolate Inhalation Solution 200mg Jet | Glycopyrrolate Inhalation Solution 500mg | Glycopyrrolate Inhalation Solution1000mg | Placebo 0.5 mL |
|---|---|---|---|---|---|---|---|
| Peak FEV1 (Change From Baseline ) | 0.212 ± 0.086 | 0.255 ± 0.068 | 0.303 ± 0.055 | 0.233 ± 0.144 | 0.177 ± 0.061 | 0.283 ± 0.069 | 0.120 ± 0.057 |
Spirometry measurements were conducted in accordance with the current ATS/ERS 2005 guidelines.
| liters | Glycopyrrolate Inhalation Solution 25mg | Glycopyrrolate Inhalation Solution 75mg | Glycopyrrolate Inhalation Solution 200mg | Glycopyrrolate Inhalation Solution 200mg Jet | Glycopyrrolate Inhalation Solution 500mg | Glycopyrrolate Inhalation Solution1000mg | Placebo 0.5 mL |
|---|---|---|---|---|---|---|---|
| FEV1 AUC0-24 Area Under the FEV1 Over Time Curve (Change From Baseline) | 1.59 ± 3.27 | 3.10 ± 2.27 | 3.19 ± 1.14 | 1.35 ± 2.74 | 1.53 ± 2.05 | 3.08 ± 1.47 | -0.11 ± 1.89 |
Pk parameters are calculated from glycopyrrolate plasma concentration analysed from serial blood samples collected between 0 and 12 hr
| pg/mL | Glycopyrrolate Inhalation Solution 200mg | Glycopyrrolate Inhalation Solution 200mg Jet | Glycopyrrolate Inhalation Solution 500mg | Glycopyrrolate Inhalation Solution1000mg |
|---|---|---|---|---|
| Cmax Maximum Observed Plasma Concentration | 177.242 ± 61.469 | 75.530 ± 64.950 | 749.872 ± 219.696 | 1534.057 ± 442.581 |
Pk parameters are calculated from glycopyrrolate plasma concentration analysed from serial blood samples collected between 0 and 12 hr
| hours | Glycopyrrolate Inhalation Solution 200mg | Glycopyrrolate Inhalation Solution 200mg Jet | Glycopyrrolate Inhalation Solution 500mg | Glycopyrrolate Inhalation Solution1000mg |
|---|---|---|---|---|
| Tmax Time to Maximum Observed Plasma Concentration | .025 ± 0.088 | 0.08 ± 0.088 | 0.25 ± 0.069 | 0.17 ± 0.093 |
Pk parameters are calculated from glycopyrrolate plasma concentration analysed from serial blood samples collected between 0 and 12 hr
| pg*h/mL | Glycopyrrolate Inhalation Solution 200mg | Glycopyrrolate Inhalation Solution 200mg Jet | Glycopyrrolate Inhalation Solution 500mg | Glycopyrrolate Inhalation Solution1000mg |
|---|---|---|---|---|
| AUC0-t Area Under the Plasma Concentration-time Curve From Time Zero to the Last Quantifiable Concentration | 429.335 ± 192.699 | 26.176 ± 16.170 | 2014.276 ± 609.911 | 4084.763 ± 827.225 |
Pk parameters are calculated from glycopyrrolate plasma concentration analysed from serial blood samples collected between 0 and 12 hr
| pg*h/mL | Glycopyrrolate Inhalation Solution 200mg | Glycopyrrolate Inhalation Solution 200mg Jet | Glycopyrrolate Inhalation Solution 500mg | Glycopyrrolate Inhalation Solution1000mg |
|---|---|---|---|---|
| AUC0-inf Area Under the Plasma Concentration-time Curve From Time Zero to Infinity | 563.416 ± 235.418 | 65.013 ± 16.750 | 2491.803 ± 736.426 | 5271.099 ± 1096.862 |
Pk parameters are calculated from glycopyrrolate plasma concentration analysed from serial blood samples collected between 0 and 12 hr.
| hour | Glycopyrrolate Inhalation Solution 200mg | Glycopyrrolate Inhalation Solution 200mg Jet | Glycopyrrolate Inhalation Solution 500mg | Glycopyrrolate Inhalation Solution1000mg |
|---|---|---|---|---|
| t1/2 Plasma Half-life | 2.947 ± 1.996 | 0.778 ± 0.465 | 6.298 ± 1.450 | 7.573 ± 1.031 |
Collected over 0-47 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Glycopyrrolate Inhalation Solution 25 μg | — | 0/6 (0%) | 2/6 (33.3%) |
| Glycopyrrolate Inhalation Solution75μg | — | 0/6 (0%) | 2/6 (33.3%) |
| Glycopyrrolate Inhalation Solution 200 μg | — | 0/6 (0%) | 4/6 (66.7%) |
| Glycopyrrolate Inhalation Solution 200μg Jet Nebulizer, | — | 0/6 (0%) | 2/6 (33.3%) |
| Glycopyrrolate Inhalation Solution 500μg | — | 0/6 (0%) | 0/6 (0%) |
| Glycopyrrolate Inhalation Solution1000mg | — | 0/6 (0%) | 2/6 (33.3%) |
| Placebo | — | 0/6 (0%) | 1/6 (16.7%) |
| Event | Glycopyrrolate Inhalation Solution 25 μg | Glycopyrrolate Inhalation Solution75μg | Glycopyrrolate Inhalation Solution 200 μg | Glycopyrrolate Inhalation Solution 200μg Jet Nebulizer, | Glycopyrrolate Inhalation Solution 500μg | Glycopyrrolate Inhalation Solution1000mg | Placebo |
|---|---|---|---|---|---|---|---|
| headacheNervous system disorders | 1/6 | 1/6 | 3/6 | 1/6 | 0/6 | 0/6 | 1/6 |
| catheter site related reactionGeneral disorders | 1/6 | 0/6 | 0/6 | 2/6 | 0/6 | 2/6 | 1/6 |
| coughRespiratory, thoracic and mediastinal disorders | 0/6 | 2/6 | 0/6 | 2/6 | 0/6 | 2/6 | 0/6 |
| nasopharyngitisInfections and infestations | 0/6 | 0/6 | 1/6 | 0/6 | 0/6 | 0/6 | 0/6 |
| rhinitisInfections and infestations | 0/6 | 0/6 | 1/6 | 0/6 | 0/6 | 0/6 | 0/6 |
| musculoskeletal discomfortMusculoskeletal and connective tissue disorders | 0/6 | 0/6 | 0/6 | 1/6 | 0/6 | 0/6 | 0/6 |
All participants in study
| Age, Categorical(Participants) | 25mg Glycopyrrolate, 200mg Gloycopyrrolate | 75mg Glycopyrrolate,500mg Glycopyrrolate,1000mg Glycopyrrolate | 200mg Glycopyrrolate Jet | Placebo | Total |
|---|---|---|---|---|---|
| <=18 years | 0 | 0 | — | — | 0 |
| Between 18 and 65 years | 2 | 3 | — | — | 5 |
| >=65 years | 4 | 3 | — | — | 7 |
| Age, Continuous(years) | 25mg Glycopyrrolate, 200mg Gloycopyrrolate | 75mg Glycopyrrolate,500mg Glycopyrrolate,1000mg Glycopyrrolate | 200mg Glycopyrrolate Jet | Placebo | Total |
|---|---|---|---|---|---|
| Mean | 66.2 ± 3.82 | 63.5 ± 8.89 | — | — | 41.67 ± 58.33 |
| Sex: Female, Male(Participants) | 25mg Glycopyrrolate, 200mg Gloycopyrrolate | 75mg Glycopyrrolate,500mg Glycopyrrolate,1000mg Glycopyrrolate | 200mg Glycopyrrolate Jet | Placebo | Total |
|---|---|---|---|---|---|
| Female | 3 | 2 | — | — | 5 |
| Male | 3 | 4 | — | — | 7 |
| Region of Enrollment(participants) | 25mg Glycopyrrolate, 200mg Gloycopyrrolate | 75mg Glycopyrrolate,500mg Glycopyrrolate,1000mg Glycopyrrolate | 200mg Glycopyrrolate Jet | Placebo | Total |
|---|---|---|---|---|---|
| United Kingdom | 6 | 6 | — | — | 12 |
No study locations are listed for this record.
The record gives a start of May 2009, a primary completion of Jul 2009 and a completion of Jul 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2018, 8 years 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pulmonary Disease, Chronic Obstructive →
Sunovion Respiratory Development Inc. →